EyePoint's DURAVYU misses primary endpoint in LUGANO wet AMD trial; Ocular Therapeutix rises
EyePoint's DURAVYU missed the primary endpoint in the pivotal LUGANO wet AMD trial, reshaping the competitive landscape for long-acting retinal therapies. Ocular Therapeutix rose 7.5% following the news, while EyePoint shares experienced a 69.96% one-day washout.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@PrismMarketView
Ocular Therapeutix ( $OCUL )rose 7.5% after EyePoint’s ( $EYPT ) DURAVYU missed the primary endpoint in the pivotal LUGANO wet AMD trial—reshaping the competitive landscape for long-acting retinal therapies. Ocular’s AXPAXLI wet AMD program remains a key catalyst, with its SOL-1 https://t.co/X851RIh1Sq
@InsiderFinancex
After a 69.96% one-day washout, $EYPT is still being led by a $7.7M $10 put block. ↘️ Options: $7.7M puts vs $79K calls ↘️ Block: $10 2026-10-16 put, 19 trades, 13,752 size ↘️ Technicals: $4.36 vs EMA21/50/200 12.34/12.84/13.2, RSI 24.26 ➡️ Level to watch: $4.50; above it the https://t.co/sGmsxgBWBc
@unemon1
Wasn't $EYPT CEO that at a Puerto Rico "cult event" ... was publicly bashing $OCUL ... and saying they had bad results on hands and withholding them from Investors? How hilarious does it sound today?